Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Appointed director
Appointed CFO
Director departure
Inv. presentation
Quarterly results
Consulting agrmnt
|
|
Alliqua BioMedical, Inc. (ADYX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/14/2019 |
8-K
| Quarterly results |
| 08/14/2019 |
8-K
| Quarterly results|
Docs:
|
"Adynxx, Inc. Condensed Consolidated Statements of Operations Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 Operating expenses Research and development $ 1,895 $ 583 $ 3,226 $ 1,269 General and administrative 1,454 598 2,317 1,292 Grant reimbursements - - Total operating expenses, net 2,245 1,181 4,345 2,561 Loss from operations Interest expense, net Other income , net - 60 60 Loss from continuing operations Loss from discontinued operations - - Net loss $ $ $ $ Net loss per basic and diluted share: Loss from continuing operations $ $ $ $ Loss from discontinued operations - - Net loss per basic and diluted share $ $ $ $ Weighted-average number of common shares outstanding - basic and diluted 5,358,882 4,569,742 4,966,491 4,569,742 Adynxx, Inc. Condensed Co..." |
|
| 11/09/2017 |
8-K
| Quarterly results|
Docs:
|
"Alliqua BioMedical, Inc. Reports Third Quarter of Fiscal Year 2017 Financial Results and Increases Fiscal Year 2017 Financial Outlook",
"Alliqua BioMedical, Inc. Engages Cowen to Assist in Evaluating Potential Strategic Alternatives YARDLEY, Pa., November 9, 2017 – Alliqua BioMedical, Inc. , a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced that it has engaged Cowen as its independent financial advisor to assist the Company in evaluating potential strategic alternatives. “The Board of Directors has decided to engage Cowen to comprehensively and systematically explore and review potential strategic alternatives. Importantly, this strategic process will not distract the organization from executing our strategic growth objectives and, in parallel, we will continue to evaluate all potential opportunities to improve the strength of our balance sheet. Our primary objective in ..." |
|
| 08/10/2017 |
8-K
| Quarterly results |
| 05/09/2017 |
8-K
| Form 8-K - Current report |
| 03/07/2017 |
8-K
| Form 8-K - Current report |
| 11/04/2016 |
8-K
| Quarterly results |
| 08/09/2016 |
8-K
| Quarterly results |
| 05/10/2016 |
8-K
| Form 8-K - Current report |
| 02/23/2016 |
8-K
| Quarterly results |
| 11/05/2015 |
8-K
| Quarterly results |
| 08/06/2015 |
8-K
| Quarterly results |
| 05/14/2015 |
8-K
| Quarterly results |
| 02/24/2015 |
8-K
| Quarterly results |
| 10/30/2014 |
8-K
| Quarterly results |
| 08/11/2014 |
8-K
| Quarterly results |
| 05/12/2014 |
8-K
| Quarterly results |
| 03/24/2014 |
8-K
| Quarterly results |
|
|